<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0015">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="ulist0010">
   <list-item id="u0010">
    <label>•</label>
    <p id="p0010">Patients with severe coronavirus disease 2019 (COVID-19) present with lymphocytopenia and T-cell exhaustion.</p>
   </list-item>
   <list-item id="u0015">
    <label>•</label>
    <p id="p0015">Persistent stimulation by severe acute respiratory syndrome coronavirus 2 leads to the inhibition of the immune system.</p>
   </list-item>
   <list-item id="u0020">
    <label>•</label>
    <p id="p0020">Immune blockade in patients with cancer supports host protective immunity.</p>
   </list-item>
   <list-item id="u0025">
    <label>•</label>
    <p id="p0025">Immune checkpoint inhibitors safely restore immunocompetence in sepsis and viral infections.</p>
   </list-item>
   <list-item id="u0030">
    <label>•</label>
    <p id="p0030">Immunostimulants should be considered as the first-line option in severe COVID-19.</p>
   </list-item>
  </list>
 </p>
</abstract>
